Add to ORKGThe U.S. Supreme Court ruling in PLIVA Inc. v. Mensing will immunize generic drug manufacturers facing failure-to-warn claims from state-law liability, and may also have implications for preemption jurisprudence more generally, says attorney Brian Wolfman and co-author Dena Feldman in this BNA Insight. The authors analyze the ruling, and offer their views on the questions that PLIVA raises about the ongoing vitality of the presumption against preemption, the standard for determining ‘‘impossibility’’ preemption, and the propriety of deference to an agency’s views on preemption
The article offers information related to the supreme courts decisions in PLIVA v. Mensing court cas...
This essay explores the role of litigation in drug safety regulation and the role of drug safety reg...
Part II of this paper analyzes the history and background of federal preemption to give context to t...
The U.S. Supreme Court ruling in PLIVA Inc. v. Mensing will immunize generic drug manufacturers faci...
The United States Supreme Court held in PLIVA v. Mensing that federal preemption immunizes generic d...
The authors state that the U.S. Supreme Court’s preemption ruling in Mutual Pharmaceutical Co. v. Ba...
The U.S. Supreme Court’s decision in Wyeth v. Levine sharply limited the availability of implied pre...
Most people think of preemption as a technical constitutional doctrine, but it is pivotally importan...
The U.S. Supreme Court’s 2011 decision in PLIVA v. Mensing left consumers of generic drugs without a...
This article discusses the prospects for preemption doctrine in the wake of the Supreme Court’s deci...
A mere five years ago, the Food and Drug Administration (the FDA ) began, for the first time in its...
The U.S. Supreme Court’s important ruling in Mutual Pharmaceutical Co., Inc. v. Bartlett concerns wh...
Following the U.S. Supreme Court’s 2011 decision in PLIVA, Inc. v. Mensing, consumers of generic pre...
On March 4, 2009, the United States Supreme Court decided Wyeth v. Levine. In that case, the Court c...
Patient safety depends on tort litigation to identify a brand-name drug’s undisclosed risks, illumin...
The article offers information related to the supreme courts decisions in PLIVA v. Mensing court cas...
This essay explores the role of litigation in drug safety regulation and the role of drug safety reg...
Part II of this paper analyzes the history and background of federal preemption to give context to t...
The U.S. Supreme Court ruling in PLIVA Inc. v. Mensing will immunize generic drug manufacturers faci...
The United States Supreme Court held in PLIVA v. Mensing that federal preemption immunizes generic d...
The authors state that the U.S. Supreme Court’s preemption ruling in Mutual Pharmaceutical Co. v. Ba...
The U.S. Supreme Court’s decision in Wyeth v. Levine sharply limited the availability of implied pre...
Most people think of preemption as a technical constitutional doctrine, but it is pivotally importan...
The U.S. Supreme Court’s 2011 decision in PLIVA v. Mensing left consumers of generic drugs without a...
This article discusses the prospects for preemption doctrine in the wake of the Supreme Court’s deci...
A mere five years ago, the Food and Drug Administration (the FDA ) began, for the first time in its...
The U.S. Supreme Court’s important ruling in Mutual Pharmaceutical Co., Inc. v. Bartlett concerns wh...
Following the U.S. Supreme Court’s 2011 decision in PLIVA, Inc. v. Mensing, consumers of generic pre...
On March 4, 2009, the United States Supreme Court decided Wyeth v. Levine. In that case, the Court c...
Patient safety depends on tort litigation to identify a brand-name drug’s undisclosed risks, illumin...
The article offers information related to the supreme courts decisions in PLIVA v. Mensing court cas...
This essay explores the role of litigation in drug safety regulation and the role of drug safety reg...
Part II of this paper analyzes the history and background of federal preemption to give context to t...